{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Agitation%2CPsychomotor",
    "query": {
      "condition": "Agitation,Psychomotor"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 127,
    "total_pages": 13,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Agitation%2CPsychomotor&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T08:12:26.864Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02129348",
      "title": "Treatment of Psychosis and Agitation in Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease",
        "Psychosis",
        "Agitation"
      ],
      "interventions": [
        {
          "name": "Lithium",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 77,
      "start_date": "2014-06",
      "completion_date": "2020-01",
      "has_results": true,
      "last_update_posted_date": "2024-05-02",
      "last_synced_at": "2026-05-22T08:12:26.864Z",
      "location_count": 4,
      "location_summary": "Miami, Florida • Belmont, Massachusetts • New York, New York + 1 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Belmont",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02129348"
    },
    {
      "nct_id": "NCT05644262",
      "title": "Life's End Benefits of cannaBidiol and tetrahYdrocannabinol",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Agitation",
        "Dementia"
      ],
      "interventions": [
        {
          "name": "T2:C100",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2023-12-18",
      "completion_date": "2026-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-05-22T08:12:26.864Z",
      "location_count": 10,
      "location_summary": "Washington D.C., District of Columbia • Miami, Florida • Tampa, Florida + 6 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05644262"
    },
    {
      "nct_id": "NCT02383004",
      "title": "Acupuncture for the Prevention of Emergence Delirium in Children Undergoing Myringotomy Tube Placement",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Delirium",
        "Psychomotor Agitation"
      ],
      "interventions": [
        {
          "name": "Acupuncture",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "1 Year to 6 Years"
      },
      "enrollment_count": 100,
      "start_date": "2015-02",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2017-01-18",
      "last_synced_at": "2026-05-22T08:12:26.864Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02383004"
    },
    {
      "nct_id": "NCT03110900",
      "title": "Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Agitation,Psychomotor",
        "Haloperidol Causing Adverse Effects in Therapeutic Use",
        "Lorazepam Causing Adverse Effects in Therapeutic Use",
        "Loxapine Causing Adverse Effects in Therapeutic Use"
      ],
      "interventions": [
        {
          "name": "Haloperidol + lorazepam",
          "type": "DRUG"
        },
        {
          "name": "Loxapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Arkansas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 2,
      "start_date": "2017-09-30",
      "completion_date": "2018-04-04",
      "has_results": true,
      "last_update_posted_date": "2018-06-11",
      "last_synced_at": "2026-05-22T08:12:26.864Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03110900"
    },
    {
      "nct_id": "NCT04947553",
      "title": "A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Agitation in Patients With Dementia of the Alzheimer's Type",
        "Alzheimer Disease",
        "Agitation, Psychomotor"
      ],
      "interventions": [
        {
          "name": "AXS-05 (dextromethorphan-bupropion)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Axsome Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "65 Years to 90 Years"
      },
      "enrollment_count": 456,
      "start_date": "2021-06-17",
      "completion_date": "2024-12-21",
      "has_results": false,
      "last_update_posted_date": "2025-12-08",
      "last_synced_at": "2026-05-22T08:12:26.864Z",
      "location_count": 45,
      "location_summary": "Peoria, Arizona • Tempe, Arizona • Long Beach, California + 35 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Temecula",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04947553"
    },
    {
      "nct_id": "NCT03513549",
      "title": "Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder",
      "overall_status": "SUSPENDED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Agitation,Psychomotor"
      ],
      "interventions": [
        {
          "name": "Loxapine 10 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexza Pharmaceuticals, Inc.",
      "sponsor_class": "UNKNOWN",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10000,
      "start_date": "2014-11-04",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2025-10-21",
      "last_synced_at": "2026-05-22T08:12:26.864Z",
      "location_count": 1,
      "location_summary": "Raleigh, North Carolina",
      "locations": [
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03513549"
    },
    {
      "nct_id": "NCT03453814",
      "title": "Music Intervention for Agitation Reduction in the Pediatric Intensive Care Unit",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Critical Illness"
      ],
      "interventions": [
        {
          "name": "Music Therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "State University of New York at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 26,
      "start_date": "2018-11-01",
      "completion_date": "2020-03-01",
      "has_results": false,
      "last_update_posted_date": "2020-03-30",
      "last_synced_at": "2026-05-22T08:12:26.864Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03453814"
    },
    {
      "nct_id": "NCT02612948",
      "title": "Quetiapine for Delirium Prophylaxis in High-risk Critically Ill Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Psychomotor Agitation"
      ],
      "interventions": [
        {
          "name": "Quetiapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Tennessee Graduate School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 82,
      "start_date": "2013-11",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2015-11-24",
      "last_synced_at": "2026-05-22T08:12:26.864Z",
      "location_count": 1,
      "location_summary": "Knoxville, Tennessee",
      "locations": [
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02612948"
    },
    {
      "nct_id": "NCT01766336",
      "title": "A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Group 1 ELND005",
          "type": "DRUG"
        },
        {
          "name": "Group 2 ELND005",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "50 Years to 95 Years"
      },
      "enrollment_count": 296,
      "start_date": "2013-01",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2019-10-21",
      "last_synced_at": "2026-05-22T08:12:26.864Z",
      "location_count": 40,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Encino, California + 35 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01766336"
    },
    {
      "nct_id": "NCT04801589",
      "title": "Goal-Directed Sedation in Mechanically Ventilated Infants and Children",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Delirium",
        "Critical Illness",
        "Sedation Complication",
        "Executive Dysfunction",
        "Post Traumatic Stress Disorder"
      ],
      "interventions": [
        {
          "name": "Dexmedetomidine",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "44 Weeks",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "44 Weeks to 11 Years"
      },
      "enrollment_count": 372,
      "start_date": "2021-05-10",
      "completion_date": "2026-09-16",
      "has_results": false,
      "last_update_posted_date": "2025-09-29",
      "last_synced_at": "2026-05-22T08:12:26.864Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04801589"
    }
  ]
}